Back to Search
Start Over
Role of nitric oxide, bradykinin B 2 receptor, and TRPV1 in the airway alterations caused by simvastatin in rats.
- Source :
-
European journal of pharmacology [Eur J Pharmacol] 2021 Dec 05; Vol. 912, pp. 174591. Date of Electronic Publication: 2021 Oct 26. - Publication Year :
- 2021
-
Abstract
- Dry cough has been reported in patients receiving statin therapy. However, the underlying mechanism or other possible alterations in the airways induced by statins remain unknown. Thus, the aim of this study was to evaluate whether simvastatin promotes alterations in airways, such as bronchoconstriction and plasma extravasation, as well as the mechanism involved in these events. Using methods to detect alterations in airway resistance and plasma extravasation, we demonstrated that simvastatin [20 mg/kg, intravenous (i.v.)] caused plasma extravasation in the trachea (79.8 + 14.8 μg/g/tissue) and bronchi (73.3 + 8.8 μg/g/tissue) of rats, compared to the vehicle (34.2 + 3.6 μg/g/tissue and 29.3 + 5.3 μg/g/tissue, respectively). N <superscript>G</superscript> -nitro-L-arginine methyl ester (L-NAME, 30 mg/kg, intraperitoneal), a nitric oxide (NO) synthase inhibitor, Icatibant [HOE 140, 10 nmol/50 μl, intratracheal (i.t.)], a bradykinin B <subscript>2</subscript> antagonist, and capsazepine (100 nmol/50 μl, i.t.), a TRPV1 antagonist, attenuated simvastatin-induced plasma extravasation. Simvastatin (5, 10 and 20 mg/kg) did not cause bronchoconstriction per se, but exacerbated the bronchoconstrictive response to bradykinin (30 nmol/kg, i.v.), a B <subscript>2</subscript> agonist (0.7 + 0.1 ml/H2O), or capsaicin (30 nmol/kg, i.v.), a TRPV1 agonist (0.8 + 0.1 ml/H2O), compared to the vehicle (0.1 + 0.04 ml/H2O and 0.04 + 0.01 ml/H2O, respectively). The bronchoconstriction elicited by bradykinin (100 nmol/kg, i.v.) in simvastatin non-treated rats was inhibited by L-NAME. The exacerbation of bronchoconstriction induced by bradykinin or capsaicin in simvastatin-treated rats was inhibited by L-NAME, HOE 140 or capsazepine. These results suggest that treatment with simvastatin promotes the release of bradykinin, which, via B <subscript>2</subscript> receptors, releases NO that can then activate the TRPV1 to promote plasma extravasation and bronchoconstriction.<br /> (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Subjects :
- Administration, Intravenous
Airway Resistance drug effects
Animals
Bradykinin administration & dosage
Bradykinin analogs & derivatives
Bradykinin pharmacology
Bradykinin B2 Receptor Antagonists administration & dosage
Bradykinin B2 Receptor Antagonists pharmacology
Bronchi metabolism
Bronchoconstriction drug effects
Capillary Permeability drug effects
Capsaicin administration & dosage
Capsaicin analogs & derivatives
Capsaicin pharmacology
Enzyme Inhibitors administration & dosage
Enzyme Inhibitors pharmacology
Injections, Intraperitoneal
Male
NG-Nitroarginine Methyl Ester administration & dosage
NG-Nitroarginine Methyl Ester pharmacology
Rats, Wistar
Simvastatin administration & dosage
TRPV Cation Channels antagonists & inhibitors
Trachea metabolism
Rats
Bronchi drug effects
Nitric Oxide metabolism
Receptor, Bradykinin B2 metabolism
Simvastatin adverse effects
TRPV Cation Channels metabolism
Trachea drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0712
- Volume :
- 912
- Database :
- MEDLINE
- Journal :
- European journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 34710369
- Full Text :
- https://doi.org/10.1016/j.ejphar.2021.174591